ArticleCancers2026
Neoadjuvant Chemotherapy Following Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Retrospective Cohort Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to compare the efficacy of neoadjuvant chemotherapy (NACT) followed by secondary cytoreductive surgery (SCS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) versus SCS with HIPEC alone in patients with platinum-sensitive recurrent ovarian cancer.
methodsA retrospective analysis was conducted on patients treated at Hospital Clínico Universitario Virgen de la Arrixaca from January 2011 to December 2024. Two cohorts were analyzed: those receiving NACT prior to SCS and HIPEC, and those undergoing SCS with HIPEC without prior NACT. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS), peritoneal progression-free survival, extraperitoneal progression-free survival, and safety.
resultsA total of 86 patients were included in the study, with 39 in the NACT group and 47 in the non-NACT group. The non-NACT cohort exhibited a significantly longer PFS of 20 months compared to 12 months in the NACT group (
conclusionsThe addition of NACT prior to SCS and HIPEC does not enhance survival outcomes for patients with platinum-sensitive recurrent ovarian cancer. In fact, those who underwent SCS with HIPEC alone demonstrated better PFS and OS, underscoring the importance of careful patient selection in optimizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.